PRLD (Prelude Therapeutics) Accounts Payable: $2.07 Mil (As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Accounts Payable?

Prelude Therapeutics PRLD +1.63% 26 Accounts Payable is $2.07 Mil as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Prelude Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $2.07 Mil.

Prelude Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($2.53 Mil) to Dec. 2025 ($3.98 Mil) but then declined from Dec. 2025 ($3.98 Mil) to Mar. 2026 ($2.07 Mil).

Prelude Therapeutics's annual Accounts Payable increased from Dec. 2023 ($4.58 Mil) to Dec. 2024 ($7.73 Mil) but then declined from Dec. 2024 ($7.73 Mil) to Dec. 2025 ($3.98 Mil).

Prelude Therapeutics Accounts Payable Related Terms

Prelude Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Accounts Payable Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 7.84 6.78 4.58 7.73 3.98

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.83 4.96 2.53 3.98 2.07
PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $2.07 Mil mean?
Prelude Therapeutics (PRLD) has a Accounts Payable of $2.07 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Accounts Payable too high?
Prelude Therapeutics' current Accounts Payable is $2.07 Mil. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Accounts Payable compare to DMAC and RCKT?
Prelude Therapeutics' Accounts Payable of $2.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Accounts Payable is $2.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Accounts Payable of $2.07 Mil. The current Accounts Payable is $2.07 Mil. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Accounts Payable is $2.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price